MA
ARNA

MYDA Advisors’s Arena Pharmaceuticals Inc ARNA Stock Holding History

MYDA Advisors’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,000
Closed -$474K – 206
2018
Q1 		$474K Buy
+12,000
New +$467K 0.32% 73

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

MYDA Advisors's ARNA Position: Q2 2018 in Review

MYDA Advisors sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2018, closing a stake of 12,000 shares — an estimated $474K sold.

MYDA Advisors first reported a position in ARNA in Q1 2018 and held it in 1 quarter. The position peaked at $474K in Q1 2018. 165 funds tracked by Wall St. Rank hold ARNA as of Q2 2018.

  • MYDA Advisors reported no remaining Arena Pharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • MYDA Advisors sold 12,000 Arena Pharmaceuticals Inc shares in Q2 2018, an estimated $474K.
  • MYDA Advisors first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 1 quarter.
  • MYDA Advisors's Arena Pharmaceuticals Inc position peaked at $474K in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2018.

Based on MYDA Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.